RETA-02: What This Research Peptide Blend Is and How It Is Studied

RETA-02 is a vendor-assigned catalog code, not a generic drug name or an FDA-approved medicine. In practice, the label usually points to a lyophilized research blend built around retatrutide — an investigational triple agonist of the GLP-1, GIP, and glucagon receptors — sometimes combined with cagrilintide, a long-acting amylin analog. Products sold as RETA-02 are marketed for laboratory research only and are not intended, tested, or approved for human use.

That distinction matters. The name itself tells you almost nothing about what is actually in the vial, how pure it is, or whether it was produced under any quality standard.

Where the RETA-02 Name Comes From

No central authority names research peptides. Vendors create their own SKUs, and the same code can mean different things at different suppliers.

• At some vendors, RETA-02 is simply a retatrutide reference standard.
• At others, it is a blend of retatrutide and cagrilintide in a fixed ratio.
• Some listings add a third component or use a different salt form entirely.

Because of that inconsistency, the only reliable way to know what a specific RETA-02 product contains is the certificate of analysis (COA) tied to the lot number, ideally issued by an independent lab.

What Is Typically in a RETA-02 Blend

The table below sums up how the compounds most often associated with RETA-02 compare with approved alternatives.

Neither retatrutide nor cagrilintide has completed regulatory review. Retatrutide is in Phase 3 development, and cagrilintide has been studied mainly in combination with semaglutide under the name CagriSema.

How Dosing Is Reported in the Research

There is no official reta cagri blend dosage chart, because no regulator has approved either compound, alone or together. Numbers that circulate online are usually pulled from separate trial protocols and then combined, which is not the same thing as a tested combination.

Published retatrutide trials used once-weekly doses of 1, 4, 8, and 12 mg, escalated slowly over several weeks. Cagrilintide trials used weekly doses ranging from 0.3 mg up to 4.5 mg. In CagriSema studies, the two drugs were given as separate injections rather than as a pre-mixed blend.

Combining two investigational peptides creates a new and untested exposure profile. No human trial has evaluated retatrutide and cagrilintide injected together as a single blend.

Anyone researching cagri and reta should keep that point in mind: the blend is a vendor invention, not a studied pharmaceutical product.

Side Effects and Safety Signals

Reported reta cagri blend side effects generally track the known profiles of GLP-1, amylin, and glucagon-based compounds. Commonly described issues include:

• Nausea, vomiting, diarrhea, and constipation
• Reduced appetite and early fullness
• Injection-site irritation
• Fatigue, headache, and dizziness
• A faster resting heart rate, which has been observed with retatrutide

More serious concerns reported across this drug class include gallbladder disease, pancreatitis, dehydration from persistent vomiting, hypoglycemia when combined with insulin or sulfonylureas, and loss of lean muscle mass during rapid weight loss.

Amylin analogs and GLP-1 drugs also carry a boxed warning about thyroid C-cell tumors in rodents, and they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.

RETA-02 vs. Tirzepatide: The Practical Comparison

The comparison most people actually search for is reta vs tirzepatide, and the answer is straightforward: tirzepatide is approved and prescribed under medical supervision, while retatrutide and cagrilintide are not.

Tirzepatide is a dual GIP/GLP-1 agonist approved for type 2 diabetes and chronic weight management. Retatrutide adds glucagon receptor activity, which in Phase 2 data produced larger average weight loss than approved agents — but those are investigational results, not a product you can legally buy as a medicine.

A research blend such as RETA-02 also has no dose standardization, no sterility guarantee, and no post-market safety monitoring. That is a fundamentally different risk profile from a prescription drug.

Sourcing, Legal Status, and Quality Red Flags

Retatrutide, cagrilintide, and any blend containing them are not approved for human use in the United States, and selling them for human consumption is not lawful. Products marketed as research chemicals sit in a gray area that regulators have repeatedly targeted.

Practical warning signs when evaluating a supplier:

1. No batch-specific third-party COA with purity and mass data
2. Vague or missing sterility and endotoxin testing
3. Pre-filled cagri reta pen formats marketed for personal use
4. Claims that a product is "pharmacy grade" or "FDA approved"
5. No verifiable business address or named testing laboratory

Much of the online discussion about cagri reta blend benefits comes from anecdotal forum posts rather than controlled trials. Anecdotes cannot tell you whether an effect came from the compound, the dose, the diet, or something else entirely.

For most people exploring weight and metabolic health, a conversation with a licensed clinician about approved options is a safer and more evidence-based starting point than an unregulated research blend.